GREY:ALEAF - Post by User
Comment by
Toweringmarson Dec 15, 2021 9:32am
132 Views
Post# 34232231
RE:RE:RE:Hexo..Redecan, Zenabis and 48 north...and then AH!
RE:RE:RE:Hexo..Redecan, Zenabis and 48 north...and then AH!Agreed, it was nice to see that they we're able to convince about 1/3 of the deb holders to convert, but I was really thinking they would have already started acting on this plan. Its painfull to see them come to the table a quarter later (knowing what we all knew) with a plan... Its like... It took you 3 months to come up with such a shallow plan? Why havnt you been acting on it already?
It was announced in a few articles now that they even approached the Quebec provincial government asking if they would take an equity position... And essentially invest in them. From that I believe the government reached out to some lenders on their behalf... Seems kind of desperate but hey, anything to stop the downward spiral I suppose.
Once tax loss wraps up I expect the sector to incrementally make slow gains.
sthinei wrote: Yeah tower. The CC had quite a big number of analysts tuned in and asking questions. One of them was about how the smaller nimble companies have been able to position themselves and take market share. Still I like hexo because as you stated those additional revs are only from 2 months worth of sales. After a full year hexo should be closer to $300 million in sales just via accounting for the full absorption of the acquisitions. Nevermind the additional international growth opportunity via EU. They also mentioned about being cash flow positive in the next few qtrs which helps tk address some of the debt concerns. I like the fact that the new CEO was running g the strategic partnership with molsons coors. I can imagine they have likely been discussing either getting an investment from them or possible outright sale. Molsons would actually look pretty good snapping up #1 cdn market share, access to EU market and all for a fraction of the $4 billion competitor Constellation brands invested in Canopy.